Ubs Group Ag Entrada Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 24,759 shares of TRDA stock, worth $133,203. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,759

Previous 51,039 51.49%

Holding current value

$133,203

Previous $461,000 63.99%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.72 - $9.23 $176,601 - $242,564	-26,280 Reduced 51.49%	24,759 $166,000
Q1 2025 May 13, 2025	SELL	$9.04 - $18.31 $18,550 - $37,572	-2,052 Reduced 3.87%	51,039 $461,000
Q4 2024 Feb 14, 2025	BUY	$15.82 - $21.59 $444,542 - $606,679	28,100 Added 112.44%	53,091 $917,000
Q3 2024 Nov 14, 2024	BUY	$13.65 - $17.86 $43,352 - $56,723	3,176 Added 14.56%	24,991 $399,000
Q2 2024 Aug 13, 2024	SELL	$11.85 - $16.45 $19,599 - $27,208	-1,654 Reduced 7.05%	21,815 $310,000
Q1 2024 May 13, 2024	BUY	$11.58 - $17.0 $11,498 - $16,881	993 Added 4.42%	23,469 $332,000
Q4 2023 Feb 09, 2024	BUY	$11.36 - $16.99 $104,114 - $155,713	9,165 Added 68.85%	22,476 $339,000
Q3 2023 Nov 09, 2023	SELL	$13.61 - $18.01 $5,130 - $6,789	-377 Reduced 2.75%	13,311 $210,000
Q2 2023 Aug 11, 2023	BUY	$11.02 - $18.01 $134,785 - $220,280	12,231 Added 839.46%	13,688 $207,000
Q1 2023 May 12, 2023	BUY	$9.58 - $16.2 $1,916 - $3,240	200 Added 15.91%	1,457 $21,000
Q4 2022 Feb 08, 2023	BUY	$13.52 - $22.89 $16,994 - $28,772	1,257 New	1,257 $16,000
Q2 2022 Aug 10, 2022	SELL	$5.49 - $12.94 $4,666 - $10,999	-850 Reduced 58.74%	597 $8,000
Q1 2022 May 16, 2022	SELL	$7.99 - $16.93 $10,922 - $23,143	-1,367 Reduced 48.58%	1,447 $13,000
Q4 2021 Feb 14, 2022	BUY	$13.7 - $35.0 $38,551 - $98,490	2,814 New	2,814 $48,000

Others Institutions Holding TRDA

# of Institutions

107

Shares Held

28.8M

Call Options Held

15.7K

Put Options Held

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $169M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account